Resource Logo
AIDS Weekly Plus

HIV-1 vaccine development: Pinning down a moving target




 



2012 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- HIV-1 is a genetically diverse collection of viruses, making it a moving target in vaccine development. In a study published in the Journal of Clinical Investigation, researchers led by Brad Jones at the University of Toronto in investigated the feasibility of eliminating HIV-infected cells by targeting cellular immune responses against a human endogenous retrovirus (HERV). HERVs are the DNA remnants of ancient infectious retroviruses that became part of the germ line cells of our ancestors. Jones and colleagues found that HIV infection stimulated the expression of HERV proteins, effectively tagging HIV-infected cells. Immune cells targeted to these proteins specifically eliminated cells infected with several different strains of HIV in vitro. This study suggests that HERV-targeted immune responses should be considered in the development of HIV vaccines (see also HIV/AIDS).

TITLE:

HERV-K-targeted T-cells eliminate diverse HIV-1/2 and SIV primary isolates

AUTHOR CONTACT:

Brad Jones

University of Toronto, Toronto, ON, CAN

Phone: 617-777-9151; E-mail: bjones.ut@gmail.com

View this article at: http://www.jci.org/articles/view/64560?key=6bb3867c449f3c243fb1

Keywords for this news article include: Genetics, HIV/AIDS, Virology, RNA Viruses, Vaccination, Immunization, Retroviridae, HIV Infections, Medical Devices, Vertebrate Viruses, Biological Products, Vaccine Development, Primate Lentiviruses, Journal of Clinical Investigation, Acquired Immunodeficiency Syndrome, Viral Sexually Transmitted Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC



 


Copyright © 2012 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in November 26, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.